- Home
- EPSN vs SLGL Comparison
EPSN vs SLGL Comparison
Compare EPSN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSN | SLGL |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EPSN | SLGL |
|---|---|---|
| Price | $4.42 | $65.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 162.0K | 21.5K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | ★ 5.63% | N/A |
| EPS Growth | ★ 11.33 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,709,605.00 | $18,970,000.00 |
| Revenue This Year | $41.35 | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | 46.76 | ★ 62.04 |
| 52 Week Low | $4.20 | $4.02 |
| 52 Week High | $8.50 | $66.20 |
Technical Indicators
Market Signals| Indicator | EPSN | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 82.82 |
| Support Level | $4.22 | $40.10 |
| Resistance Level | $4.65 | $66.20 |
| Average True Range (ATR) | 0.18 | 4.10 |
| MACD | -0.02 | 2.17 |
| Stochastic Oscillator | 30.43 | 96.21 |
Price Performance
Historical ComparisonAbout EPSN Epsilon Energy Ltd.
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.